Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Key Points

• Short interest rose 48.9% to 227,041 shares as of August 14, representing approximately 0.4% of Innate Pharma’s outstanding shares.
• Analysts were broadly positive: five rated the stock a Buy and one rated it a Sell, producing a consensus rating of Moderate Buy and an average price target of $6.67.
• IPHA shares fell 2.3% to $2.12 in recent trading, while institutional ownership remained limited at 0.16%; the stock’s 52-week range was $1.17 to $2.71.

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) saw a significant growth in short interest in August. As of August 14th, there was short interest totaling 227,041 shares, a growth of 48.9% from the July 30th total of 152,432 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 721,354 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of Innate Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IPHA. Jane Street Group LLC acquired a new position in Innate Pharma during the 4th quarter worth approximately $162,000. OLD Mission Capital LLC acquired a new stake in Innate Pharma in the fourth quarter valued at approximately $50,000. Finally, Millennium Management LLC bought a new stake in shares of Innate Pharma during the fourth quarter valued at approximately $36,000. 0.16% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IPHA. HC Wainwright upped their target price on Innate Pharma from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, August 10th. BTIG Research lifted their price target on shares of Innate Pharma from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Citigroup raised shares of Innate Pharma from a "buy" rating to an "outperform" rating in a research note on Tuesday, August 11th. Leerink Partners upgraded Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 price objective for the company in a report on Tuesday, August 11th. Finally, Weiss Ratings raised Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.67.

Innate Pharma Trading Down 2.3%

IPHA traded down $0.05 during midday trading on Tuesday, hitting $2.12. The company had a trading volume of 4,968 shares, compared to its average volume of 86,989. The stock's 50 day moving average price is $1.93 and its 200 day moving average price is $1.72. Innate Pharma has a 52 week low of $1.17 and a 52 week high of $2.71.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.